Latest news from Pharmetheus
Pharmetheus continues to monitor the challenges presented by the COVID-19 pandemic and its effects on our company and in the field of clinical drug development. Read more about our approach and latest updates here.
Pharmetheus featured in Pharma Tech Outlook magazine
Our CEO, Dr Peter A Milligan, has been interviewed by the Pharma Tech Outlook magazine. Read more about how we change the model informed drug development landscape of the pharmaceutical industry with our cutting-edge tools and methods, from early clinical trials to drug approval. Read the full interview here.
Top Pharma Analytics company
We are honoured that Pharmetheus has been listed as one of the top 10 pharma analytics companies in Europe by the Pharma Tech Outlook magazine for our Model Informed Drug Development consulting services. Read more here.
American Society of Hematology Annual Meeting & Exposition 2020
We are present at the American Society of Hematology Annual Meeting & Exposition 2020. On Saturday, December 5, Daniel Röshammar will present on age and body weight adjusted dosing of dabigatran etexilate in children with venous thromboembolism (Abstract 891). He is also co-author to the Abstract 236; Anticoagulant effects of dabigatran on coagulation laboratory parameters in paediatric patients: combined data from five paediatric clinical trials.
Additional PBPK publication
Our Pharmetheus colleague Erik Sjögren is co-author to one additional new publication on physiologically based biopharmaceutics models, including case studies. This workshop report summarizes the proceedings of Day 3 of a three-day workshop on “Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls. Link to publication
Introduction to our MIDD framework
We are advancing model informed drug development. In this video, Peter A Milligan describes our framework and some benefits of adopting these solutions across the project portfolio in terms of improved decision making, efficiency and return of investment.
Welcome Fanny Gallais!
We are happy to have Fanny onboard as a MIDD consultant. Her research experience includes PK/PD modeling and simulations of preclinical and clinical data in oncology. Fanny will first work from her home office in France and then join our Uppsala office in Sweden in January. See her bio here.
See the poster presentation of Population RTTE analysis of exacerbations in asthma patients by our MIDD Consultant Robin Svensson, presented at the American Conference on Pharmacometrics, November 2020
Welcome Andrea Henrich!
We are happy to have Andrea onboard as a MIDD consultant. Her research experience, from academia as well as pharmaceutical industry, includes PK/PD modeling and simulations in different therapeutic areas and concentration-QT analysis. Andrea will work from our Basel office in Switzerland. See her bio here
Free Virtual Speed Consulting
Pharmetheus will offer virtual professional pharmacometrics consulting sessions (~30 min), free of charge, between 5th and 20th of November in connection to the ACoP meeting.
Read more about the offer here.
New MIDD publication
Read more on the importance of collaboration for successful implementation Model Informed Drug Development. Richard Anziano, Chief Statistician and Peter A Milligan, CEO at Pharmetheus gives their perspective on this topic in the latest issue of Clinical Pharmacology & Therapeutics. Link to publication
New PBPK publication
Our Pharmetheus colleague Erik Sjögren is co-author to a new publication on physiologically based biopharmaceutics models. This workshop report summarizes the proceedings of Day 1 of a three-day workshop on “Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls”. Link to publication
Welcome Quentin Leirens!
We are happy to have Quentin onboard in our Enabling team. Previously he was as a scientist at SGS Exprimo (2011-2020). His research experience includes model-based simulations for supporting drug development decision making, many of which have been submission projects. He has been extensively involved in the development of the Simulo software for clinical trial simulation. Quentin will work from his home office in Belgium. See his bio here.
If you are interested in our services, please fill out the form below.
Our way of working, with traceability and accountability from data programming to report delivery, is well adapted to, and highly compatible with, current regulatory requirements.